TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development.
Add to these features the high scientific standards, informal atmosphere, and active participation by the world’s leading phase 1 investigators, and you will understand why the TAT Congress has become the prime international anticancer drug development meeting.
Fast Facts: Targeted Anticancer Therapies Congress 2020
- Expecting over 400 participants
- No parallel sessions
- Possibility to host a satellite symposium
- More than 60 internationally renowned faculty
- Excellent networking opportunities
Past attendance
ESMO gratefully acknowledges the valuable contribution of the following organisations in the TAT Congresses over the years.
Past attendees | ||
|---|---|---|
4clinics |
Celgene France |
MSD |
AbbVie |
Daiichi Sankyo Cancer Enterprise |
Novartis |
Active Motif |
ESMO |
Orion Pharma |
Adaptive Biotechnologies |
GSK |
Pfizer |
Amgen |
Illumina |
PharmaMar |
Amoy Diagnostics Co, Ltd. |
Innate Pharma |
Pierre Fabre |
Astex Pharmaceuticals, Inc. |
INC |
Roche |
AstraZeneca France |
Incyte Corporation |
Sanofi |
AstraZeneca MedImmune |
Immodulon Therapeutics |
Servier Oncology |
Bavarian Nordic |
Ipsen Pharma |
Syneos Health |
Bayer |
Janssen Pharmaceutical Research & Development, L.C.C. |
SIRIC-SOCRATE |
BlueDNAcompanion |
Lilly |
Takeda |
Boehringer Ingelheim |
Merck |
Tesaro |
Bristol-Myers Squibb |
MedImmune |
|
How can I participate in ESMO Targeted Anticancer Therapies Congress 2020?
At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress.
Contact the ESMO Strategic Partnerships Team for more details. We look forward to hearing from you!
Who has already signed up?
ESMO gratefully acknowledges the valuable contribution the following organisations have made to the Targeted Anticancer Therapies Congress 2020. (As of February 2020):
